Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition
Tian Li, Shi Hu
Topics & Concepts
CetuximabColorectal cancerMAPK/ERK pathwayCancer researchMEK inhibitorMedicineProtein kinase BCancerEGFR inhibitorsApoptosisOncologyInternal medicineEpidermal growth factor receptorSignal transductionChemistryBiochemistryColorectal Cancer Treatments and StudiesHepatocellular Carcinoma Treatment and PrognosisMelanoma and MAPK Pathways